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Summary Single-chain urokinase-type plasminogen activator (pro-uPA) is bound to a specific surface receptor on ovarian cancer HOC-I cells that is incompletely saturated. Saturation of uncovered receptors by uPA polypeptides with intact amino-terminal fragment (ATF) derived from pro-uPA by limited proteolysis (human leucocyte elastase [HLE] or V8 protease) has been studied. HOC-I cells preferentially invaded reconstituted basement membranes in a time-and plasminogen-dependent manner. This process was inhibitable by preincubation with uPA polypeptides in the medium at levels which suggested that complete saturation of cell surface uPA receptors occurred. This result indicates that occupation of uPA receptors by enzymatically inactive uPA fragments or prevention of rebinding of pro-uPA synthesised by tumour cells to the receptors specifically reduces the invasion of the tumour cells through basement membranes in vitro.
Cancer cells produce and secrete urokinase-type plasminogen activator (uPA) in an enzymatically inactive proenzyme form (single-chain uPA; pro-uPA) (Dano et al., 1985; Stoppelli et al., 1985) . Secreted pro-uPA can immediately bind to the specific uPA receptors on tumour cell surfaces with high affinity. The receptor-bound pro-uPA may be converted to the enzymatically active two-chain uPA (high molecular weight-uPA; HMW-uPA) by the proteinases plasmin, kallikrein, or cell surface-associated cathepsin B Estreicher et al., 1989; Kobayashi et al., 1991) . The initial activation of receptor-bound pro-uPA with subsequent activation of plasminogen and procollagenase on the tumour cell surfaces may be required for the proteolytic degradation of tumour stromas and basement membranes (Liotta et al., 1983; Mignatti et al., 1986) . It has been demonstrated that cell-associated uPA is not sensitive to specific plasminogen activator inhibitors (Stoppelli et al., 1986) . Thus the uPA receptor focusses the proteolytic activity of uPA to the cancer cell surface. The increased invasive potential of tumour cells is correlated well with cell surface-associated proteolytic activity due to the interaction between uPA and its surface receptor. Evidence for the role of an uPA-plasmincollagenase activation cascade in cancer cells is provided (Mignatti et al., 1986) . The constitutive saturation of uPA receptors with pro-uPA synthesised by the same cell may be a property of tumour cells, providing a mechanism for their invasiveness (Stoppelli et al., 1986) .
The receptor-binding domain within the uPA-molecule has been localised to the amino acid sequence 18-32 of the amino-terminal fragment (ATF) of uPA (Appella et al., 1987) . ATF comprising the so called Growth Factor-like domain (GFD) and the Kringle has been shown to bind to uPA receptors on normal and neoplastic cells with the same affinity as pro-uPA (Vassalli et al., 1985; DelRosso et al., 1985; Cubellis et al., 1986; Appella et al., 1987; Estreicher et al., 1989; Stephens et al., 1989; Picone et al., 1989) . ATF, lacking the B-chain, does not show enzymatic activity (Stoppelli et al., 1985; Cubellis et al., 1986 Various test systems have been devised to study the mechanism of invasiveness and inhibition of experimental metastasis in vitro. These have suggested that proteinase inhibitors and specific antibodies for collagenase, uPA and plasmin prevented cancer cell invasion of chick chorioallantoic membrane (Ossowski & Reich, 1980; Ossowski & Reich, 1983; Ossowski, 1988) , human amnion (Mignatti et al., 1986) , and reconstituted basement membranes (Gehlsen et al., 1984; Kleinman et al., 1986; Terranova et al., 1986; Albini et al., 1987) . The aim of this study is to determine (1) how to obtain uPA fragments/polypeptides with intact GFD by limited proteolysis, and (2) whether uPA polypeptides with intact GFD can inhibit HOC-I tumour cell invasion in an in vitro reconstituted basement membrane assay.
Materials and methods
Interaction ofpro-uPA with several proteinases Pro-uPA (Saruplase, Grunenthal GmbH, Stolberg, FRG; Green Cross, Co., Japan) was incubated with human leucocyte elastase (HLE) or V8 protease, if not otherwise specified, at a molar ratio of 4:1 or 50:1, respectively, as a function of time at 37TC in phosphate buffered saline, pH 7.4 (PBS). In order to obtain plasmin-treated ATF, pro-uPA was first incubated (6 h, 37C) with a 10-fold lower concentration (molar ratio) of plasmin in 50 mM phosphate buffer, 0.1 M NaCl, pH 6.0. Subsequently, this pro-uPA/plasmin solution was adjusted to pH 8.0 and then further incubated (12 h, 37'C). The ATF formed was separated from LMWuPA by ion exchange column chromatography (Gunzler et al., 1982) . The subfragments of the ATF polypeptides with intact GFD of pro-uPA were obtained by limited proteolysis with HLE or V8 protease, while ATF with cleaved GFD was obtained by plasmin treatment. 538 H. KOBAYASHI et al.
an aliquot of sample buffer (0.5 M Tris-HCl, pH 6.8, 2.5% SDS, 25% glycerol, with and without 5% 2-mercaptoethanol), boiling for 3 min, and then immediately analysed by 5-15% sodium dodecyl sulfate-poly acrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) . Proteins separated by SDS-PAGE were electroblotted onto polyvinylidine difluoride (PVDF) membrane (Millipore, Bedford, MA), using a semidry electroblotting apparatus (Parmacia-LKB) at 40 mA/gel (90 min, 23°C). After transfer, the sheets were incubated with mouse monoclonal antibody (moAB) 377 (1.0 jig ml-'), reacting with the A-chain of pro-uPA, moAB GFDl (0.45 pg ml-'), specific for a peptide sequence within Growth Factor-like domain (GFD) of uPA, and moAB 98.6 (0.51Agml-'), reacting with the B-chain of pro-uPA in Tris- buffered saline containing 2% BSA, pH 7.5 (TBS-BSA) (1 h, 23°C). The sheets were incubated with biotin-conjugated antimouse IgG (0.5 fg ml-', Sigma) in TBS-BSA (1 h, 23°C), followed by incubation with avidin-peroxidase (4 jsg ml-', Sigma) in TBS-BSA (1 h, 23°C), and developed with 0.1% 4-chloro-l-naphthol, 37% ethanol, 0.005% hydrogen peroxide in TBS.
Isolation of the A TF-fractions from HLE-, V8 protease-, or plasmin-treated pro-uPA Crude ATF-fraction of uPA-molecule was first obtained as a side-fraction by the same method as the preparation of twochain uPA/LMW-uPA by plasmin (Gunzler et al., 1982) . The ATF polypeptide formed was separated from two-chain uPA/LMW-uPA by ion-exchange column chromatography. Two mg crude ATF-fraction was subjected to cationexchange chromatography Mono S HR 5/5 column applying a HPLC-system equilibrated with 50 mm sodium acetate buffer, pH 5.0. After washing with equilibrating buffer, bound proteins were eluted with a linear salt gradient (0.15-0.5M NaCI) in sodium acetate buffer for 35 min at 23°C. Further purification was achieved by reversed-phase HPLC. Polypeptides were eluted with a linear gradient from 0 to 70% acetonitrile in 0.1% trifluoro-acetic acid/H20. Synthesis of uPA peptides uPA20-30 (consisting of amino acid sequences from Val20 to Tyr3O of uPA molecule) and uPA17-34 (from Glyl7 to Pro34), representing sequences within the GFD of uPA, were synthesised by the Merrifield-solid-phase method. These synthetic peptides were purified to homogeneity by reversedphase HPLC.
N-terminal amino acid sequence determination and amino acid analysis The proteinase-mediated cleavage site in pro-uPA was determined by N-terminal amino acid sequence analysis (Schmitt et al., 1989) . Separated uPA polypeptides were subjected to six Edman degradation cycles. Sequence analyses were performed with a Beckman 890C spinning cup sequenator.
Cells and culture
Ovarian cancer cell line, designated as HOC-I, was established from a recurrent region of ovarian endometrioid carcinoma (Fujii, 1989) . The cells were maintained under an atmosphere of 5% CO2 in RPMI 1640 medium supplemented with 10% foetal calf serum (FCS; GIBCO). The addition of purified human plasminogen (100 fig ml-'; Sigma) to HOC-I cells produced significant increases in the specific activity of cell-associated urokinase-type plasminogen activator (uPA), indicating that the HOC-I cells express enzymatically inactive uPA (pro-uPA) on their cellular surfaces, which is cleaved by trace contamination of plasmin in the plasminogen preparation (Stoppelli et al., 1986) .
U937 promyeloid cells were grown in RPMI 1640 medium supplemented with 10% FCS. Differentiated U937 cells were obtained by incubation in the above medium containing IM phorbol 12-myristate-13-acetate (PMA). A 3-day incubation period resulted in 60% adherent cells. Adherent cells were detached with PBS containing 1 mM EDTA, harvested by centrifugation (1,200 rpm, 10 min), and used for the binding and competition experiments . PMAstimulated U937 cells were treated with 50 mM glycine HCI, 0.5 M NaCl, pH 3.0, first, to dissociate receptor-bound uPA. After centrifugation, the cell pellet was adjusted to a density of 106 cells ml-' in PBS containing 0.1% BSA, pH 7.4 (PBS-BSA). uPA polypeptides derived from pro-uPA by limited proteolysis were used as competitors. 1.5 nM of FITC-prouPA in the presence or absence of unlabelled competitors was added to the cells (30 min, 4°C). Nonspecific binding of FITC-pro-uPA to U937 cells was determined in the presence of an excess (O.IlfM) of parent pro-uPA.
Cell attachment assay
The fibronectin solution (10 tLg ml-' PBS) was incubated in the 96-well microtiter plate (Costar, Cambridge, MA; 2 h, 23°C) (Ruoslahti et al., 1982) . The unattached protein was removed by washing three times with PBS. For the assay, the HOC-I cells were washed three times with PBS-BSA, then 1 mm EDTA was added, and the cells were removed by agitation until they were detached. The cells were then collected by centrifugation, washed with PBS-BSA, and were dispersed by pipetting until a single cell suspension was obtained. Before the last centrifugation, a sample was taken, and cell numbers and viability by trypan blue exclusion were determined. The cells are suspended in PBS-BSA at a concentration of 2 x 106 cells ml '. One hundred tlI of RPMI 1640 containing plasminogen (100 lgml-') in the absence or presence of uPA polypeptides, as described in the Figure 9 legend, was added to each well (1 h, 37°C). This was followed by the addition of 1001gl of the cell suspension. After the plate is incubated (2 h, 37°C), the unattached cells are removed simply by tossing out the medium and washing. Under optimal conditions, about 70% of these cells remain attached to the well after washing (Control). The cells are then fixed with 3% paraformaldehyde and stained with 1% toluidine blue, 3% formaldehyde in PBS, and attached cells are counted with an Olympus light microscope ( x 200). The data are expressed as the number of attached cells at randomly chosen area (each sample was assayed using triplicate wells and each well was counted in three areas).
Cell invasion assay Invasiveness of tumour cells was determined using a modification of the Membrane Invasion Culture System (MICS) (Gehlsen et al., 1984; Kleinman et al., 1986; Terranova et al., Albini et al., 1987) . Briefly, polycarbonate filters, 8-,sm pore size (Costar) were coated with an extract of basement membrane components (Matrigel, 50 ptg/filter, 1.2 gtg mm-2) and dried (2 h, 37°C). Blind well Boyden chambers were filled with 600 1l RPMI 1640, 0.1% BSA in the lower compartment and coated filters mounted in the chamber. The cells to be studied were collected by short exposure to EDTA resuspended in PBS-BSA, and shaking as described above. The in vitro cell invasion assay was carried out to study the role of cell-associated uPA in tumour cell invasion by attempting to saturate uncovered uPA receptors by ATF or enzymatically inactive uPA polypeptides (modifying agents). We added these modifying agents under the conditions described below. The HOC-I cells were pretreated with each modifying agent (at the concentrations noted) as described in the Figure 8 legend, typically for 60 min at 23°C.
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Then 100 ,il cell suspension (2 x 106 ml-') was placed in the upper compartment of the chamber and followed by the addition of 100 pl serum-free medium in the presence of plasminogen (100 lig ml-'). Human fibroblast conditioned media were placed in the lower compartment as a source of chemoattractants. Under these conditions, few cells died within 24 h in preliminary experiments. The chemotactic assays were conducted in a similar fashion without coating of Matrigel. After incubation (24 h, 37°C) the filters were then removed, fixed and stained. All material from the upper surface of the filter was carefully removed by scraping with a cotton tip, and invasive cells adhering to the lower surface of the filter were quantitated with a light microscope ( x 200) . The data are expressed as the number of cells on the bottom surface of the filter at randomly chosen area (each sample was assayed using triplicate filters and filters were counted in three areas). (Figure 4) . The locations of the respective cleavage sites are illustrated in Figure 5 . ,ug/ml ,ug/ml ,ug/ml U/mi jig/ml
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[HLE] < *, P < 0.05; **, P < 0.01; ***, P < 0.001 Figure 8 Effects of uPA polypeptides on tumour cell invasion. The HOC-I cells were tested in an in vitro reconstituted basement membranes invasion assay. The numbers of cells that had attached to the lower surface of the filter at 24 h were used to calculate invasion. One hundred tLg ml1 l plasminogen was routinely added to the upper chamber and each cell invasion assay was performed in the presence of plasminogen. Each uPA polypeptide (see Text) and serine proteinase inhibitors (trasylol [500 U ml-'] and epsilon-aminocapronic acid [E-ACA; 500 tLg ml-']) were preincubated with HOC-I cells 60 min before the cells were plated on the matrigel. Trasylol and E-ACA reduced the invasion by about 70 -80% (P < 0.001). The concentration used are not cytotoxic. The inhibitory effect of the serine proteinase inhibitors was dose-dependent (see Kobayashi et al., 1992b) . Control experiments were carried out in the absence of uPA polypeptides with and without plasminogen (100 ttg ml -). For each experiment three replicates were performed. Mean and SD of three experiments are shown. The similar results were obtained when these agents were added to the wells before the cells were seeded into the culture wells (data not shown here).
thetic uPA peptides, uPA20-30 and uPA17-34, had essentially no effect. To investigate the more complete dose relationship of ATF [HLE] and ATF[V8] on the inhibition of HOC-I cell invasion, different doses of each uPA polypeptide were preincubated with HOC-I cells 60 min before the cells were plated on matrigel. We confirmed that attempts with ATF[V8] and ATF [HLE] , but not ATF [PL] , showed a significant inhibition of invasion in a dose-dependent manner, and gave more of a sense of reproducibility of this phenomena in replicate experiments (Table I) . Also, the data showed that the dose of 101igml-' used in our experiments achieved near-maximal effects.
The chemotactic response of the cells was also tested to determine whether the inhibition of the HOC-I cells ability to invade was due to the uPA polypeptide inhibiting this response ( Figure 9 ). The cells tested here showed a good chemotactic response in the presence of uPA polypeptides. These results indicate that there are no effects of uPA polypeptides on cancer cell chemotaxis, because the cancer cells are able to migrate to chemoattractants even in the presence of uPA polypeptides.
In addition, the effects of uPA polypeptides used in the experiments on HOC-I cell attachment have been studied. Under optimal conditions, 70% of these cells remain attached to the well after washing. No inhibition of attachment to fibronectin was seen with any of uPA polypeptides. The results are shown in Figure 9 .
Discussion
The central molecule in the surface pathway for plasminogen activation appears to be the uPA receptor (Vassalli, et al., 1985; Blasi et al., 1987; Estreicher et al., 1989 SD<20% in all samples; cP<0.05; dp < 0.O l. Pannell, 1987; Schmitt et al., 1989; Schmitt et al., 1991; Kobayashi et al., 1991; Goretzki et al., 1992) . Receptorbound pro-uPA can be converted to the two-chain form of uPA-molecule, or alternatively can first be activated by plasmin or cathepsin B and then bind to the uPA receptor Kobayashi et al., 1991) . Receptor molecules could be hidden by the enzymatically inactive ATF, after the proeolytic cleavage of receptor-bound uPA at position 135 by plasmin, which might represent a regulatory mechanism sensing the excess of plasmin at the cell surface (Kobayashi et al., 1992a) .
Our preliminary study indicates that (1) ovarian cancer derived HOC-I cells used in this study have uPA molecules on their cell surfaces and most of the cell-associated uPA on the cell surfaces are enzymatically inactive pro-uPA, that (2) pro-uPA is bound to a specific surface receptor that is incompletely saturated, that (3) cell-associated pro-uPA can be converted to HMW-uPA by plasmin and cathepsin B, and that (4) its activity can be inhibited by an antibody against B-chain of uPA (Kobayashi et al., 1992b and for inhibition of tumour cell invasion.
Various investigators (Liotta et al., 1980; Thorgeirsson et al., 1982; Ostrowski et al., 1986; Bergman et al., 1986; Nakajima et al., 1987; Reich et al., 1988; Hearing et al., 1988; Cajot et al., 1989; Baker et al., 1990; Ellis et al., 1990) have shown that tumour cells may express surface-associated uPA activity and that inhibition of this activity by specific antibodies or proteinase inhibitors leads to a decrease in the invasive potential of tumour cells.
The use of antibodies in therapy of humans is highly restricted. Our data indicate that enzymatically inactive receptor-bound uPA polypeptides can also lead to a decrease in the invasive potential of this tumour cell line and would be worth testing in livo. The uPA receptor on HOC-I cells would be hidden by the enzymatically inactive uPA polypeptides, which leads to a decrease in a proteolytic action on tumour cell surfaces.
The incompleteness with which the competitive receptorbound uPA polypeptides block invasion indicates that uPA is not sufficient in invasion mechanisms, suggesting that HOC-I cells have a significant uPA/plasmin-independent proteinase activity (Kobayashi et al., 1992b 
